Bristol-Myers Squibb Co (NYSE:BMY) Shares Purchased by Jacobs & Co. CA

Jacobs & Co. CA boosted its position in Bristol-Myers Squibb Co (NYSE:BMY) by 1.4% during the second quarter, Holdings Channel.com reports. The fund owned 65,648 shares of the biopharmaceutical company’s stock after purchasing an additional 886 shares during the quarter. Jacobs & Co. CA’s holdings in Bristol-Myers Squibb were worth $2,977,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of BMY. James Investment Research Inc. increased its holdings in Bristol-Myers Squibb by 36.5% in the first quarter. James Investment Research Inc. now owns 819 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 219 shares during the last quarter. Lowe Brockenbrough & Co. Inc. increased its holdings in Bristol-Myers Squibb by 0.5% in the first quarter. Lowe Brockenbrough & Co. Inc. now owns 43,384 shares of the biopharmaceutical company’s stock valued at $2,070,000 after buying an additional 220 shares during the last quarter. Squar Milner Financial Services LLC increased its holdings in Bristol-Myers Squibb by 5.6% in the first quarter. Squar Milner Financial Services LLC now owns 4,209 shares of the biopharmaceutical company’s stock valued at $200,000 after buying an additional 223 shares during the last quarter. Clear Harbor Asset Management LLC increased its holdings in Bristol-Myers Squibb by 2.4% in the first quarter. Clear Harbor Asset Management LLC now owns 9,637 shares of the biopharmaceutical company’s stock valued at $460,000 after buying an additional 229 shares during the last quarter. Finally, Dynamic Advisor Solutions LLC increased its holdings in Bristol-Myers Squibb by 1.0% in the first quarter. Dynamic Advisor Solutions LLC now owns 22,750 shares of the biopharmaceutical company’s stock valued at $1,085,000 after buying an additional 235 shares during the last quarter. Hedge funds and other institutional investors own 77.37% of the company’s stock.

Several analysts recently weighed in on BMY shares. ValuEngine lowered Bristol-Myers Squibb from a “sell” rating to a “strong sell” rating in a report on Tuesday, July 2nd. Atlantic Securities raised Bristol-Myers Squibb from a “neutral” rating to an “overweight” rating and set a $63.00 price objective for the company in a report on Wednesday. Argus lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $46.36 price objective for the company. in a report on Monday, May 20th. Zacks Investment Research raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $54.00 price objective for the company in a report on Tuesday, May 7th. Finally, UBS Group decreased their target price on Bristol-Myers Squibb from $55.00 to $51.00 and set a “neutral” rating for the company in a research note on Thursday, June 13th. One analyst has rated the stock with a sell rating, eight have given a hold rating and nine have issued a buy rating to the company’s stock. Bristol-Myers Squibb has a consensus rating of “Hold” and an average price target of $55.88.

Shares of NYSE BMY traded down $0.19 during midday trading on Wednesday, hitting $46.30. 194,258 shares of the company’s stock were exchanged, compared to its average volume of 16,761,281. The company has a debt-to-equity ratio of 1.51, a quick ratio of 3.75 and a current ratio of 3.88. The business’s 50 day moving average is $45.29. The stock has a market cap of $77.40 billion, a price-to-earnings ratio of 11.66, a P/E/G ratio of 2.34 and a beta of 0.73. Bristol-Myers Squibb Co has a twelve month low of $42.48 and a twelve month high of $63.69.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, July 25th. The biopharmaceutical company reported $1.18 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.06 by $0.12. The business had revenue of $6.27 billion during the quarter, compared to the consensus estimate of $6.10 billion. Bristol-Myers Squibb had a return on equity of 47.63% and a net margin of 26.14%. The business’s revenue was up 10.0% on a year-over-year basis. During the same period in the previous year, the firm posted $1.01 earnings per share. As a group, equities research analysts predict that Bristol-Myers Squibb Co will post 4.26 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Thursday, August 1st. Shareholders of record on Friday, July 5th were given a $0.41 dividend. The ex-dividend date of this dividend was Wednesday, July 3rd. This represents a $1.64 dividend on an annualized basis and a yield of 3.54%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 41.21%.

In other Bristol-Myers Squibb news, insider Karen Murphy Santiago sold 3,065 shares of the company’s stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $47.56, for a total value of $145,771.40. Following the completion of the sale, the insider now directly owns 3,066 shares in the company, valued at $145,818.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Robert J. Bertolini bought 11,000 shares of the business’s stock in a transaction on Wednesday, July 31st. The stock was purchased at an average price of $44.72 per share, with a total value of $491,920.00. Following the completion of the transaction, the director now directly owns 11,397 shares of the company’s stock, valued at $509,673.84. The disclosure for this purchase can be found here. Corporate insiders own 0.13% of the company’s stock.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Recommended Story: Relative Strength Index

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.